N/A
Completed N=2,738,161
Epidemiologic Study Of Diabetes And Cancer Risk
Diabetes Mellitus, Type 2, Cancer
Source: ClinicalTrials.gov NCT02958995 ↗
Enrolled (actual)
2,738,161
Serious AEs
—
Results posted
Mar 2017
Primary outcomePrimary: Age and Sex-Standardized Incidence Rates for the 10 Most Common Cancers Stratified by Diabetes Status — 380.2; 421.9; 308.0; 281.9 Incidence per 100,000 person-years
Summary
The purpose of this study was to evaluate whether treatment with pioglitazone is associated with risk of incident cancer at the 10 most common sites in a cohort of participants with recognized diabetes along with the assessment of association between diabetes severity and cancer risk.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Age and Sex-Standardized Incidence Rates for the 10 Most Common Cancers Stratified by Diabetes Status |
380.2; 421.9; 308.0; 281.9; 291.8; 310.7 | — |
| PRIMARY Hazard Ratio for Risk of 10 Common Cancers Associated With Diabetes |
0.81; 0.77; 1.01; 0.98; 0.99; 0.84 | — |
Eligibility Criteria
Inclusion Criteria: 1. has been in the KPNC diabetes registry Diabetes Mellitus (DM) registry, aged 40 years or older and are members of KPNC as of January 1, 1997 and had no prior diagnosis of the cancer of interest.
Data sourced from ClinicalTrials.gov (NCT02958995). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.